Rhythm Biosciences Ltd. (AU:RHY) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Rhythm Biosciences Ltd has achieved its 2024 milestones, including the release of its 2nd Generation ColoSTAT® Beta kits for colorectal cancer detection. The company secured $3.23 million from the R&D Tax Incentive and raised $3.5 million through a share placement, positioning itself for further commercialization efforts. With plans for a commercial launch in late 2025, Rhythm is actively engaging with regulatory bodies and laboratory partners across key markets.
For further insights into AU:RHY stock, check out TipRanks’ Stock Analysis page.